NORTHWEST BIOTHERAPEUTICS INC
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| | NORTHWEST BIOTHERAPEUTICS, INC.(Registrant) | |
|---|---|---|
| Date: April 15, 2026 | By: | /s/ Linda F. Powers |
| | | Linda F. Powers, |
| | | President and Chief Executive Officer Principal Executive OfficerPrincipal Financial and Accounting Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| /s/ Linda F. Powers | | President and Chief Executive Officer | | April 15, 2026 |
| Linda F. Powers | | Principal Executive Officer | | |
| | | Principal Financial and Accounting Officer | | |
| | | | | |
| /s/ Alton L. Boynton | | Director | | April 15, 2026 |
| Alton L. Boynton | | | | |
| | | | | |
| /s/ Navid Malik | | Director | | April 15, 2026 |
| Dr. Navid Malik | | | | |
| | | | | |
| /s/ Pat Sarma | | Director | | April 15, 2026 |
| Pat Sarma | | | | |
| | | | | |
| /s/ J. Cofer Black | | Director | | April 15, 2026 |
| J. Cofer Black | | | | |
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| Reports of Independent Registered Public Accounting Firm (PCAOB ID 00677) | F-2 |
|---|---|
| | |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-5 |
| | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 | F-6 |
| | |
| Consolidated Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2025 and 2024 | F-7 |
| | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-8 |
| | |
| Notes to the Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.